Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) is leveraging artificial intelligence, epigenetics, and genetics to address coronary heart disease, the leading cause of death in the United States. According to the American Heart Association (AHA), cardiovascular disease accounted for more than 940,000 deaths in 2022, with annual health care costs projected to rise from $393 billion in 2020 to $1.4 trillion by 2050.
The company's approach uses a simple blood draw to detect coronary heart disease, including forms that standard diagnostic methods often miss. This earlier detection, combined with high sensitivity, gives Cardio Diagnostics a defensible clinical position in the market. Recent commercial and regulatory milestones further strengthen the investment case for the company.
Heart disease has been the nation's number one killer for decades, and the problem is worsening. Traditional diagnostic tools have limitations, but Cardio Diagnostics' precision cardiovascular medicine platform aims to bridge that gap. By applying AI and epigenetic analysis, the company seeks to identify heart disease at earlier stages, potentially reducing the growing healthcare burden.
For more information on Cardio Diagnostics, visit the company's newsroom at https://ibn.fm/CDIO.
InvestorWire, a specialized communications platform, distributes press releases for private and public companies. It is part of the Dynamic Brand Portfolio @IBN, which provides access to wire solutions, editorial syndication to over 5,000 outlets, press release enhancement, social media distribution, and corporate communications solutions. For more details, see https://www.InvestorWire.com/Disclaimer.
